Boston Scientific (BSX) revenue breakdown
By segment, Cardiovascular is the largest at 66% of fiscal 2025 revenue, growing 37% a year over 4 years.
By product, Interventional Cardiology & Vascular Therapies is the largest at 23% of fiscal 2025 revenue; Watchman grew fastest, 43% a year over 5 years.
Revenue by segment
Fiscal years, as Boston Scientific reports them in its 10-K filings; fiscal 2025 total $20.1B.
| Segments | 2018 | 2021 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|
| Cardiovascular | $3.8B | $7.2B | $8.8B | $10.8B | $13.2B | 66% |
| MedSurg | $3.0B | $4.6B | $5.4B | $6.0B | $6.8B | 34% |
| Rhythm and Neuro | $3.0B | — | — | — | — | — |
Revenue by product
Fiscal years, as Boston Scientific reports them in its 10-K filings; fiscal 2025 total $20.1B.
| Products | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|
| Interventional Cardiology & Vascular Therapies | — | — | — | — | — | $3.8B | $4.2B | $4.6B | 23% |
| Electrophysiology | $311M | $329M | $287M | $365M | $585M | $800M | $1.9B | $3.3B | 17% |
| Endoscopy | $1.8B | $1.9B | $1.8B | $2.1B | $2.2B | $2.5B | $2.7B | $2.9B | 15% |
| Urology | $1.2B | $1.4B | $1.3B | $1.6B | $1.8B | $2.0B | $2.2B | $2.7B | 13% |
| Cardiac Rhythm Management | $2.0B | $1.9B | $1.7B | $2.0B | $2.1B | $2.2B | $2.3B | $2.3B | 12% |
| Watchman | — | — | $324M | $829M | $1.0B | $1.3B | $1.5B | $2.0B | 10% |
| Neuromodulation | $779M | $873M | $761M | $909M | $917M | $976M | $1.1B | $1.2B | 6% |
| Interventional Oncology & Embolization | — | — | — | — | — | $736M | $856M | $996M | 5% |
| Global Interventional Cardiology (IC) Reporting Unit | $2.6B | $2.8B | — | — | — | — | — | — | — |
| Interventional Cardiology Therapies | — | — | $2.0B | $2.2B | $2.2B | — | — | — | — |
| Global Peripheral Interventions (PI) Reporting Unit | $1.2B | $1.4B | $1.6B | $1.8B | $1.9B | — | — | — | — |
| Other | — | $81M | $219M | — | -$60M | — | — | — | — |
Revenue by region
Fiscal years, as Boston Scientific reports them in its 10-K filings; fiscal 2025 total $20.1B.
| Regions | 2018 | 2019 | 2020 | 2021 | 2023 | 2025 | Share |
|---|---|---|---|---|---|---|---|
| U.S. | $5.5B | $6.2B | $5.7B | $6.9B | $8.4B | $12.9B | 64% |
| Europe, Middle East and Africa | — | — | — | — | $2.9B | $3.5B | 17% |
| Asia-Pacific | — | — | — | — | $2.4B | $3.1B | 15% |
| Latin America and Canada | — | — | — | — | $560M | $678M | 3% |
| Non-US | $4.3B | $4.6B | $4.2B | $5.0B | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for BSX.
Open BSX in InvestinglyQuestions
Where does Boston Scientific make its money?
In fiscal 2025, by segment: Cardiovascular $13.2B, MedSurg $6.8B.
From Boston Scientific's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.